Previous 10 | Next 10 |
SAN CARLOS, Calif. , May 9, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today reported financial results for the first quarter ended March 31, 2019 and provided an update on rec...
SAN CARLOS, Calif. , May 9, 2019 /PRNewswire/ -- A new clinical study shows that Natera's Signatera™ test identified colorectal cancer recurrence up to 16.5 months earlier than radiologic imaging by detecting traces of tumor DNA in the blood after surgery. The test also identifie...
SAN CARLOS, Calif. , May 7, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA) today announced the publication of a clinical validation study demonstrating that its Signatera™ molecular residual disease (MRD) test was highly prognostic of recurrence in patients with bladder ...
SAN CARLOS, Calif. , May 6, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA) today announced that the U.S. Food and Drug Administration (FDA) has granted "Breakthrough Device" designation for its Signatera™ test for use in the post-surgical detection and quantification of ...
SAN CARLOS, Calif. , May 2, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that it will release results for its first quarter ended March 31, 2019 , after the mar...
Quick Take CareDx ( CDNA ) announced it has agreed to acquire OTTR Complete Transplant Management for about $16 million. OTTR has developed organ transplant patient tracking software. CDNA gains a reasonably-priced and well-integrated system as it seeks to capitalize on a growing trans...
Natera (NASDAQ: NTRA ) has priced its public offering of 5,263,158 common shares at $19.00 per share. More news on: Natera, Inc., Healthcare stocks news, Read more ...
SAN CARLOS, Calif. , April 17, 2019 /PRNewswire/ -- Natera, Inc . (Nasdaq: NTRA), a global leader in cell-free DNA testing, today announced the pricing of its underwritten public offering of 5,263,158 shares of its common stock at a price to the public of $19.00 per share. Clos...
SAN CARLOS, Calif. , April 16, 2019 /PRNewswire/ -- Natera, Inc . (Nasdaq: NTRA), a global leader in cell-free DNA testing, today announced the launch of a proposed follow-on public offering of $100,000,000 of shares of its common stock. In addition, Natera expects to grant t...
SAN CARLOS, Calif. , April 16, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), Cancer Research UK , Imperial College London and the University of Leicester , today announced the publication of results of a clinical study demonstrating that the Signatera...
News, Short Squeeze, Breakout and More Instantly...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its second quarter ended June 30, 2024, after the market close on Aug. 8, 2024. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET...
Study reports high accuracy of Signatera for surveillance of MCC patients, suggests potential to reduce frequency of surveillance imaging Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in the Journal of Clinical Oncolog...
2024-07-23 12:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...